The results from a new Phase 3 trial, which involved more than 32,000 participants, could boost confidence in the vaccine, which was originally developed by Oxford University.
The lawsuit showed that the vaccine was approved and did not identify any safety concerns, the company said. An independent committee found “an increased risk of thrombosis or thrombosis-marked events among the 21,583 participants receiving at least one dose of the vaccine,” according to AstraZeneca.
The new data came from a Phase 3 clinical trial conducted in the US, Chile and Peru. AstraZeneca says it plans to submit the findings to a scientific journal for peer-reviewed.
For its part, Oxford said the findings add to “previous test data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom” according to a press release from the United Kingdom. university.
As part of the trial, more than 32,000 volunteers recruited across all ages received either two doses of the vaccine or a placebo vaccine at four-week intervals.
An emergency study by the European Medicines Agency (EMA) concluded last Thursday that the vaccine is “safe and effective” in preventing coronavirus and is “unrelated to an increase in total risk of thromboembolic events, or blood clots. ”
The vaccine was co-designed by vaccine co-designer and Oxford University professor of Vaccinology Sarah Gilbert to provide “further evidence on the safety and efficacy” of the vaccine.
Chief Investigator for Vaccination and Professor of Pediatric Disease and Immunology at Oxford University Andrew Pollard said AstraZeneca’s data were “consistent with the results of Oxford-led trials”, adding that he expected a “strong impact against COVID-19 across all ages and for people of all backgrounds from the widespread use of the vaccine. “